Author: Keefe, Anthony D.; Pai, Supriya; Ellington, Andrew
Title: Aptamers as therapeutics Cord-id: sw1hki4r Document date: 2010_1_1
ID: sw1hki4r
Snippet: Nucleic acid aptamers can be selected from pools of random-sequence oligonucleotides to bind a wide range of biomedically relevant proteins with affinities and specificities that are comparable to antibodies. Aptamers exhibit significant advantages relative to protein therapeutics in terms of size, synthetic accessibility and modification by medicinal chemistry. Despite these properties, aptamers have been slow to reach the marketplace, with only one aptamer-based drug receiving approval so far.
Document: Nucleic acid aptamers can be selected from pools of random-sequence oligonucleotides to bind a wide range of biomedically relevant proteins with affinities and specificities that are comparable to antibodies. Aptamers exhibit significant advantages relative to protein therapeutics in terms of size, synthetic accessibility and modification by medicinal chemistry. Despite these properties, aptamers have been slow to reach the marketplace, with only one aptamer-based drug receiving approval so far. A series of aptamers currently in development may change how nucleic acid therapeutics are perceived. It is likely that in the future, aptamers will increasingly find use in concert with other therapeutic molecules and modalities.
Search related documents:
Co phrase search for related documents- acid cleave and activity high: 1
- acid ligand and active site: 1, 2
- acid ligand and active site protein: 1
- acid ligand and activity loss: 1
Co phrase search for related documents, hyperlinks ordered by date